CN110381942B - 包含珀奈莫德的药物组合 - Google Patents

包含珀奈莫德的药物组合 Download PDF

Info

Publication number
CN110381942B
CN110381942B CN201880017102.0A CN201880017102A CN110381942B CN 110381942 B CN110381942 B CN 110381942B CN 201880017102 A CN201880017102 A CN 201880017102A CN 110381942 B CN110381942 B CN 110381942B
Authority
CN
China
Prior art keywords
active ingredient
pharmaceutical composition
teriflunomide
treatment
leflunomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880017102.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110381942A (zh
Inventor
马丁尼·克劳泽
蕾蒂西娅·普佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuvies Pharmaceutical Laboratory Co Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN110381942A publication Critical patent/CN110381942A/zh
Application granted granted Critical
Publication of CN110381942B publication Critical patent/CN110381942B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
CN201880017102.0A 2017-03-14 2018-03-13 包含珀奈莫德的药物组合 Active CN110381942B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/055994 2017-03-14
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (2)

Publication Number Publication Date
CN110381942A CN110381942A (zh) 2019-10-25
CN110381942B true CN110381942B (zh) 2022-12-27

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880017102.0A Active CN110381942B (zh) 2017-03-14 2018-03-13 包含珀奈莫德的药物组合

Country Status (24)

Country Link
US (3) US11723896B2 (cg-RX-API-DMAC7.html)
EP (1) EP3595657A1 (cg-RX-API-DMAC7.html)
JP (3) JP7281406B2 (cg-RX-API-DMAC7.html)
KR (1) KR102574562B1 (cg-RX-API-DMAC7.html)
CN (1) CN110381942B (cg-RX-API-DMAC7.html)
AU (2) AU2018233109B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018894A2 (cg-RX-API-DMAC7.html)
CA (1) CA3056301C (cg-RX-API-DMAC7.html)
CL (1) CL2019002525A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008510A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190464A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000257A (cg-RX-API-DMAC7.html)
EA (1) EA201992117A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19073317A (cg-RX-API-DMAC7.html)
IL (1) IL269239B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20190207A1 (cg-RX-API-DMAC7.html)
MA (1) MA49822A (cg-RX-API-DMAC7.html)
MX (1) MX390941B (cg-RX-API-DMAC7.html)
NI (1) NI201900092A (cg-RX-API-DMAC7.html)
PE (1) PE20191489A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502110A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907308UA (cg-RX-API-DMAC7.html)
UA (1) UA125756C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018167030A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684553A (zh) * 2012-08-03 2015-06-03 前进制药公司 治疗多发性硬化症的组合疗法
WO2016091996A1 (en) * 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
ES2237553T3 (es) 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
EP1381356B1 (en) * 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43728E1 (en) 2003-11-21 2012-10-09 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
AU2005295511A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
TWI460166B (zh) 2006-11-23 2014-11-11 Actelion Pharmaceuticals Ltd 製備２-亞胺基-四氫噻唑-４-酮衍生物之新穎方法
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
PL2278960T5 (pl) * 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
NZ598744A (en) 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
US20180185308A1 (en) 2015-06-18 2018-07-05 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684553A (zh) * 2012-08-03 2015-06-03 前进制药公司 治疗多发性硬化症的组合疗法
WO2016091996A1 (en) * 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Also Published As

Publication number Publication date
AU2018233109A1 (en) 2019-08-22
CA3056301A1 (en) 2018-09-20
EA201992117A1 (ru) 2020-02-17
JP2024096962A (ja) 2024-07-17
KR20190122716A (ko) 2019-10-30
MX2019010874A (es) 2019-12-11
KR102574562B1 (ko) 2023-09-04
US12527772B2 (en) 2026-01-20
US20200069655A1 (en) 2020-03-05
AU2018233109B2 (en) 2023-09-28
US20240139161A1 (en) 2024-05-02
IL269239B1 (en) 2023-03-01
SG11201907308UA (en) 2019-09-27
IL269239A (en) 2019-11-28
MA49822A (fr) 2020-06-17
US11723896B2 (en) 2023-08-15
CO2019008510A2 (es) 2019-10-21
ECSP19073317A (es) 2019-11-30
NI201900092A (es) 2020-03-11
WO2018167030A1 (en) 2018-09-20
CL2019002525A1 (es) 2020-02-07
PE20191489A1 (es) 2019-10-21
CR20190464A (es) 2019-11-26
US20260108501A1 (en) 2026-04-23
JOP20190207A1 (ar) 2019-09-10
PH12019502110A1 (en) 2020-03-16
JP2023030091A (ja) 2023-03-07
CN110381942A (zh) 2019-10-25
JP7281406B2 (ja) 2023-05-25
CA3056301C (en) 2024-10-01
JP2020510045A (ja) 2020-04-02
IL269239B2 (en) 2023-07-01
DOP2019000257A (es) 2020-09-15
UA125756C2 (uk) 2022-06-01
BR112019018894A2 (pt) 2020-04-14
AU2023274118A1 (en) 2023-12-21
EP3595657A1 (en) 2020-01-22
AU2023274118B2 (en) 2024-12-12
MX390941B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
US12527772B2 (en) Pharmaceutical combination comprising ponesimod
EA041630B1 (ru) Фармацевтическая комбинация, содержащая понесимод

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250924

Address after: Villeurbanne, France

Patentee after: Zhuvies Pharmaceutical Laboratory Co., Ltd.

Country or region after: France

Address before: Swiss A Skei Weil

Patentee before: ACTELION PHARMACEUTICALS Ltd.

Country or region before: Switzerland